Orphan Drug Designation Granted for AB103 for Necrotizing Soft Tissue Infections

Atox Bio was granted orphan drug designation by the FDA for its drug candidate AB103 for the treatment of necrotizing soft tissue infections (NSTI). AB103 is a rationally designed short peptide acting as a CD28 modulator regulating the host's inflammatory response. AB103 has successfully completed a Phase 1 study and will shortly go into a Phase 2 proof of concept study evaluating its clinical benefit when administered in addition to standard of care in up to 56 NSTI patients at 7 surgical trauma centers.

For more information visit www.atoxbio.com.